Larvol Delta - Responses-to-sonelokimab-are-robust-following-prior-exposure-to-biologics-in-patients-with-moderatetosevere-HS-pooled-analysis-of-the-VELA1-and-VELA2-Phase-3-trials

sonelokimab (M1095) - Avillion, MoonLake Immunotherap

https://pagv3.virtual-meeting.org/eadv/eadvcongress2026/en-GB/pag/presentation/63488

Brian Kirby

Aug 6, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next